 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | BR105 / Zhejiang Hisun
Preclinical, Journal: Preclinical characterization of the novel anti-SIRPĪ± antibody BR105 that targets the myeloid immune checkpoint. (Pubmed Central) - May 12, 2022
BR105 has a favorable safety profile and shows no adverse effects on T cell functionality. These data support further clinical development of BR105, especially as a therapeutic agent to enhance efficacy when used in combination with tumor-targeting antibodies or antibodies that target other immune checkpoints.
- ||| lumistobart (BR105) / Zhejiang Hisun
New P1 trial, Metastases: BR105-I: Phase I Clinical Study of BR105 Injection (clinicaltrials.gov) - Apr 28, 2022
P1, N=162, Not yet recruiting, Sponsor: Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd